Thermo Fisher Scientific (NYSE:TMO – Get Free Report) and Seer (NASDAQ:SEER – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.
Analyst Ratings
This is a breakdown of current ratings and price targets for Thermo Fisher Scientific and Seer, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Thermo Fisher Scientific | 0 | 6 | 17 | 1 | 2.79 |
| Seer | 1 | 0 | 0 | 2 | 3.00 |
Thermo Fisher Scientific presently has a consensus price target of $619.41, suggesting a potential upside of 7.31%. Seer has a consensus price target of $4.00, suggesting a potential upside of 82.65%. Given Seer’s stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Thermo Fisher Scientific.
Risk & Volatility
Insider and Institutional Ownership
89.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 11.3% of Seer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Thermo Fisher Scientific and Seer’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Thermo Fisher Scientific | 15.04% | 17.09% | 8.12% |
| Seer | -464.78% | -26.58% | -23.51% |
Valuation & Earnings
This table compares Thermo Fisher Scientific and Seer”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Thermo Fisher Scientific | $44.56 billion | 4.79 | $6.70 billion | $18.59 | 31.05 |
| Seer | $16.58 million | 7.26 | -$73.60 million | ($1.24) | -1.77 |
Thermo Fisher Scientific has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.
Summary
Thermo Fisher Scientific beats Seer on 9 of the 15 factors compared between the two stocks.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
About Seer
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
